Previous basic and clinical studies have shown that increased serum ADA activity assumes an important role in the pathophysiological processes of organ-specific and systemic autoimmune diseases (29, 30); the former includes myasthenia gravis and Graves’ disease, and the latter includes rheumatoid arthritis and systemic lupus erythematosus. The gene discussed is ADA; the disease is Graves disease.